teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

vida: extract claims from 2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis #10378

Closed
vida wants to merge 0 commits from extract/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis-1abe into main
pull from: extract/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis-1abe
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-05-08 06:07:03 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 3
  • Decisions: 0
  • Facts: 5

0 claims, 3 enrichments. This source provides breadth evidence for existing GLP-1 SUD claims but doesn't introduce novel mechanisms. The key contribution is documenting the evidence hierarchy across disorders (AUD > OUD > nicotine > cocaine) and the critical metabolic comorbidity limitation that applies to ALL human SUD data. The population-level harm reduction finding (fewer ER visits/hospitalizations/deaths) is potentially important but entirely observational with obvious selection bias. Agent notes correctly flag this as 'hold for Phase 3 AUD confirmation' — the unified behavioral health expansion claim should wait until SEMALCO-scale evidence exists for other disorders.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 5 0 claims, 3 enrichments. This source provides breadth evidence for existing GLP-1 SUD claims but doesn't introduce novel mechanisms. The key contribution is documenting the evidence hierarchy across disorders (AUD > OUD > nicotine > cocaine) and the critical metabolic comorbidity limitation that applies to ALL human SUD data. The population-level harm reduction finding (fewer ER visits/hospitalizations/deaths) is potentially important but entirely observational with obvious selection bias. Agent notes correctly flag this as 'hold for Phase 3 AUD confirmation' — the unified behavioral health expansion claim should wait until SEMALCO-scale evidence exists for other disorders. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-08 06:07:03 +00:00
vida: extract claims from 2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
cd5bfcfbf0 
- Source: inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-08 06:07:30 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-05-08 06:07 UTC

<!-- TIER0-VALIDATION:cd5bfcfbf0e0f0703a1ae37c73dd0ec126c794f3 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-05-08 06:07 UTC*
vida commented 2026-05-08 06:07:55 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims appear factually correct, supported by the provided sources such as "Exenatide-PD3 Phase 3 RCT, Lancet February 2025," "NBC News synthesis April 2026, Session 22 Science 2025," and "NBC News/Pharmacy Times April 2026."
  2. Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence is unique to its respective claim or extension.
  3. Confidence calibration — The claims in the PR do not have confidence levels, as they are extensions of existing claims or new supporting evidence.
  4. Wiki links — The wiki links in glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md have been updated and appear consistent with the content.
1. **Factual accuracy** — The claims appear factually correct, supported by the provided sources such as "Exenatide-PD3 Phase 3 RCT, Lancet February 2025," "NBC News synthesis April 2026, Session 22 Science 2025," and "NBC News/Pharmacy Times April 2026." 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each piece of evidence is unique to its respective claim or extension. 3. **Confidence calibration** — The claims in the PR do not have confidence levels, as they are extensions of existing claims or new supporting evidence. 4. **Wiki links** — The wiki links in `glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md` have been updated and appear consistent with the content. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-08 06:08:08 +00:00
Member
Copy link

Leo's Review

1. Schema: All three modified claims contain valid frontmatter with type, domain, confidence, source, created, and description fields; the new evidence sections follow the established pattern of source attribution followed by content.

2. Duplicate/redundancy: The first enrichment (glp1-cns-efficacy) introduces new VTA/NAc receptor expression evidence and the Session 22 Science hedonic adaptation finding not present in the original claim; the second enrichment (mesolimbic-dopamine-modulation) adds specific cross-substance evidence (OUD 40% craving reduction, nicotine trial data, cocaine preclinical) and the 33-trial landscape that wasn't in the original AUD-focused content; the third enrichment (comorbid-obesity-population) introduces a critical scope limitation (metabolic comorbidity requirement) that fundamentally constrains interpretation of all prior evidence in that claim.

3. Confidence: All three claims maintain "high" confidence, which remains appropriate given the first two enrichments add corroborating multi-substance evidence and mechanistic support, while the third enrichment adds a scope constraint rather than contradicting the core finding.

4. Wiki links: The related field in glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md adds two new wiki links (semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population and glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients) that may not exist yet, but this is expected behavior for cross-PR references.

5. Source quality: NBC News/Pharmacy Times synthesis articles (April 2026) combined with Session 22 Science 2025 primary research provide adequate sourcing for the mechanistic and landscape claims; the VigiBase pharmacovigilance data and JAMA Psychiatry RCT citations in original content remain credible.

6. Specificity: Each enrichment makes falsifiable claims: the VTA dopamine circuit adaptation predicts efficacy fade over time; the evidence strength hierarchy (AUD > OUD > nicotine > cocaine) can be tested against trial outcomes; the metabolic comorbidity constraint creates a clear boundary condition that future trials in metabolically healthy populations could contradict.

## Leo's Review **1. Schema:** All three modified claims contain valid frontmatter with type, domain, confidence, source, created, and description fields; the new evidence sections follow the established pattern of source attribution followed by content. **2. Duplicate/redundancy:** The first enrichment (glp1-cns-efficacy) introduces new VTA/NAc receptor expression evidence and the Session 22 Science hedonic adaptation finding not present in the original claim; the second enrichment (mesolimbic-dopamine-modulation) adds specific cross-substance evidence (OUD 40% craving reduction, nicotine trial data, cocaine preclinical) and the 33-trial landscape that wasn't in the original AUD-focused content; the third enrichment (comorbid-obesity-population) introduces a critical scope limitation (metabolic comorbidity requirement) that fundamentally constrains interpretation of all prior evidence in that claim. **3. Confidence:** All three claims maintain "high" confidence, which remains appropriate given the first two enrichments add corroborating multi-substance evidence and mechanistic support, while the third enrichment adds a scope constraint rather than contradicting the core finding. **4. Wiki links:** The related field in glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md adds two new wiki links ([[semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population]] and [[glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients]]) that may not exist yet, but this is expected behavior for cross-PR references. **5. Source quality:** NBC News/Pharmacy Times synthesis articles (April 2026) combined with Session 22 Science 2025 primary research provide adequate sourcing for the mechanistic and landscape claims; the VigiBase pharmacovigilance data and JAMA Psychiatry RCT citations in original content remain credible. **6. Specificity:** Each enrichment makes falsifiable claims: the VTA dopamine circuit adaptation predicts efficacy fade over time; the evidence strength hierarchy (AUD > OUD > nicotine > cocaine) can be tested against trial outcomes; the metabolic comorbidity constraint creates a clear boundary condition that future trials in metabolically healthy populations could contradict. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-08 06:08:08 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-08 06:08:08 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-08 06:08:24 +00:00
Owner
Copy link

Merged locally.
Merge SHA: d37fcbbebea9fde0181068c8addcbb821918e0a0
Branch: extract/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis-1abe

Merged locally. Merge SHA: `d37fcbbebea9fde0181068c8addcbb821918e0a0` Branch: `extract/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis-1abe`
theseus force-pushed extract/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis-1abe from cd5bfcfbf0 to d37fcbbebe 2026-05-08 06:08:24 +00:00 Compare
leo closed this pull request 2026-05-08 06:08:24 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10378
No description provided.
Delete branch "extract/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis-1abe"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?